novan
strengthens
financial
leadership
appointments
chief
financial
officer
seasoned
industry
executive
board
directors
john
gay
vice
president
finance
corporate
controller
years
financial
accounting
experience
appointed
chief
financial
officer
james
bierman
seasoned
industry
executive
extensive
strategic
financial
expertise
business
acumen
former
ceo
coo
cfo
owens
minor
appointed
board
directors
morrisville
globe
newswire
novan
company
novan
nasdaq
novn
today
announced
appointment
john
gay
serve
company
chief
financial
officer
appointment
james
bierman
board
directors
mr
gay
accomplished
finance
accounting
executive
years
professional
experience
demonstrated
track
record
strategic
financial
planning
analysis
accessing
capital
markets
public
company
technical
regulatory
reporting
course
career
mr
gay
joined
novan
may
recently
served
vice
president
finance
corporate
controller
addition
principal
financial
officer
corporate
secretary
company
john
established
key
member
team
since
joining
novan
perfectly
suited
take
role
chief
financial
officer
proven
financial
leader
responsible
executing
company
financial
strategy
provided
us
sufficient
capital
advance
pivotal
phase
study
molluscum
potentially
transformational
catalyst
company
data
targeted
commented
paula
brown
stafford
chairman
chief
executive
officer
novan
bierman
seasoned
executive
brings
extensive
strategic
financial
expertise
including
financial
operational
strategies
mergers
acquisitions
strategic
alliances
enterprise
risk
management
investor
relations
novan
board
directors
thrilled
welcome
bierman
board
directors
proven
industry
leader
key
executive
experience
amassed
course
career
including
served
ceo
coo
cfo
owens
minor
fortune
company
strategic
expertise
integral
asset
bring
new
perspective
board
two
key
appointments
believe
financial
leadership
never
stronger
believe
continue
make
tremendous
progress
towards
novan
next
phase
growth
continued
stafford
bierman
experienced
independent
director
mentored
assisted
professional
development
financial
executives
senior
members
management
course
career
addition
executive
leadership
experience
including
serving
president
chief
executive
officer
owens
minor
nyse
omi
well
executive
vice
president
chief
financial
officer
quintiles
transnational
corporation
formerly
nasdaq
qtrn
also
served
multiple
public
company
boards
including
currently
serving
member
board
directors
tenet
healthcare
corporation
nyse
thc
fortune
company
mimedx
group
nasdaq
otc
mdxg
novan
novan
clinical
biotechnology
company
focused
leveraging
proprietary
nitric
oxide
based
technology
platform
generate
macromolecular
new
chemical
entities
nces
treat
multiple
indications
dermatology
men
women
health
infectious
diseases
gastroenterology
conditions
significant
unmet
needs
company
lead
product
candidate
topical
antiviral
gel
treatment
molluscum
contagiosum
currently
evaluated
pivotal
phase
clinical
study
company
believes
topical
therapy
rapid
treatment
benefit
approved
would
address
important
need
treatment
molluscum
statements
press
release
contains
statements
including
limited
statements
related
pharmaceutical
development
nitric
product
candidates
intention
advance
development
certain
product
candidates
timing
reporting
findings
results
programs
currently
process
statements
subject
number
risks
uncertainties
could
cause
actual
results
differ
materially
expectations
including
limited
risks
uncertainties
clinical
development
process
including
among
others
length
expense
ability
enroll
patients
reliance
third
parties
potential
delays
impacts
whether
result
pandemic
factors
results
earlier
research
preclinical
clinical
trials
may
predictive
results
conclusions
interpretations
later
research
activities
additional
trials
risks
related
regulatory
approval
process
lengthy
inherently
unpredictable
including
risk
product
candidates
may
approved
additional
studies
may
required
approval
delays
may
occur
may
obtain
funding
sufficient
complete
regulatory
development
process
ability
retain
key
personnel
ability
obtain
additional
funding
enter
strategic
business
relationships
necessary
useful
development
product
candidates
operational
disruptions
result
pandemic
including
delays
disruptions
enrollment
conduct
phase
trial
risks
uncertainties
described
annual
report
filed
sec
form
twelve
months
ended
december
amended
subsequent
filings
sec
statements
speak
date
press
release
novan
disclaims
intent
obligation
update
statements
reflect
events
circumstances
date
statements
except
may
required
law
investor
media
contact
jenene
thomas
jtc
team
llc
novn
